Oral Wegovy gains approval

The new thing in weight-loss drugs is not a stronger shot. It is a tablet you swallow once a day that uses the same semaglutide ingredient behind Wegovy, and the Food and Drug Administration cleared it for adults with obesity or overweight plus a weight-related condition in December 2025. (fda.gov) Semaglutide copies a gut hormone called glucagon-like peptide-1, which is one of the body’s “meal is here” signals. That signal slows stomach emptying and helps people feel full sooner, which is why the drug can lower calorie intake without acting like an old-style stimulant diet pill. (fda.gov) For years, the catch was delivery. Stomach acid tends to break peptide drugs apart the way rain ruins a paper note, so semaglutide first became famous as a weekly injection instead of a pill. (nejm.org) Novo Nordisk tested whether a 25 milligram oral version could still move the scale in a large late-stage study called OASIS 4. The trial enrolled 307 adults without diabetes at 23 sites in the United States, Canada, and Germany, and ran for 72 weeks with 64 weeks of treatment. (clinicaltrials.gov, nejm.org) People in OASIS 4 were randomly assigned in a 2-to-1 split to semaglutide or placebo, and both groups also got diet and exercise support. By week 64, the semaglutide group had an estimated mean weight change of minus 13.6%, versus minus 2.2% for placebo. (nejm.org) The study did not just show an average. People taking the pill were significantly more likely to lose at least 5%, 10%, 15%, and 20% of body weight, and they also reported better physical function scores on a quality-of-life scale. (nejm.org) The tradeoff looked familiar to anyone who has followed this class of drugs. Gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, and abdominal pain were the most common problems, and in OASIS 4, gastrointestinal adverse events were reported in 74.0% of the semaglutide group versus 42.2% of placebo. (nejm.org, fda.gov) The label also carries the same boxed warning that follows injectable semaglutide. Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, because rodent studies found thyroid C-cell tumors. (fda.gov) What changes in real life is convenience. The tablet gives people who avoid needles another route into the same drug family, although it comes with more rules than an ordinary pill: it is taken on an empty stomach in the morning with up to 4 ounces of water, and patients wait 30 minutes before eating. (fda.gov, managedhealthcareexecutive.com) Novo Nordisk spent much of 2023 and 2024 struggling to keep injectable Wegovy in stock, so the supply piece matters almost as much as the approval. The company said manufacturing for the pill was already underway in North Carolina and that it was preparing a full United States launch in early January 2026. (appliedclinicaltrialsonline.com, prnewswire.com) That turns this from a lab result into a market fight. By April 2026, Novo Nordisk was already publishing head-to-head-style comparisons against Eli Lilly’s oral rival orforglipron, which shows the next obesity-drug battle is moving from weekly pens to daily tablets. (novonordisk.com, msn.com)